Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHL NASDAQ:DSGN NASDAQ:TKNO NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25744,051 shsN/ADSGNDesign Therapeutics$4.28+7.8%$3.93$2.60▼$7.77$243.75M1.5877,625 shs76,915 shsTKNOAlpha Teknova$4.23-2.5%$5.06$3.45▼$10.37$226.05M0.32359,455 shs606,997 shsTVRDTvardi Therapeutics$23.92+3.5%$25.24$8.13▼$34.31$223.89M0.2134,451 shs14,114 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+91.81%DSGNDesign Therapeutics0.00%+12.04%+9.18%+18.23%+0.94%TKNOAlpha Teknova0.00%-0.24%-12.06%-40.08%-0.47%TVRDTvardi Therapeutics0.00%-8.70%-12.51%+2,391,999,900.00%+2,391,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADSGNDesign Therapeutics0.1248 of 5 stars0.01.00.00.00.72.50.0TKNOAlpha Teknova2.9097 of 5 stars3.83.00.00.02.51.70.6TVRDTvardi TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/ADSGNDesign Therapeutics 0.00N/AN/AN/ATKNOAlpha Teknova 3.50Strong Buy$10.00136.41% UpsideTVRDTvardi Therapeutics 3.00Buy$64.25168.60% UpsideCurrent Analyst Ratings BreakdownLatest ACHL, TVRD, DSGN, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025TKNOAlpha TeknovaStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.007/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$52.006/12/2025TVRDTvardi TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$78.005/21/2025TVRDTvardi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ATKNOAlpha Teknova$37.74M5.99N/AN/A$1.55 per share2.73TVRDTvardi Therapeutics$7.14M31.36N/AN/A($3.02) per share-7.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-27.15%-26.07%N/ATKNOAlpha Teknova-$26.75M-$0.48N/AN/AN/A-55.24%-25.98%-18.07%N/ATVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-595.39%-710.04%-79.00%N/ALatest ACHL, TVRD, DSGN, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A8/7/2025Q2 2025TKNOAlpha Teknova-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 million5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04DSGNDesign TherapeuticsN/A28.3728.37TKNOAlpha Teknova0.175.644.71TVRDTvardi TherapeuticsN/A32.4831.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%DSGNDesign Therapeutics56.64%TKNOAlpha Teknova13.81%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%DSGNDesign Therapeutics23.50%TKNOAlpha Teknova12.50%TVRDTvardi Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableTKNOAlpha Teknova24053.44 million46.76 millionNot OptionableTVRDTvardi Therapeutics809.36 million9.07 millionN/AACHL, TVRD, DSGN, and TKNO HeadlinesRecent News About These CompaniesRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comTvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James FinancialJuly 14, 2025 | marketbeat.comEquities Analysts Offer Predictions for TVRD FY2025 EarningsJuly 14, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics (NASDAQ:TVRD) Earns Overweight Rating from Analysts at Cantor FitzgeraldJuly 11, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 2.4% - What's Next?July 11, 2025 | marketbeat.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.comRecently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock UpsideJune 12, 2025 | benzinga.comTvardi Therapeutics Inc (TVRD)June 7, 2025 | investing.comTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHL, TVRD, DSGN, and TKNO Company DescriptionsAchilles Therapeutics NASDAQ:ACHLAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Design Therapeutics NASDAQ:DSGN$4.28 +0.31 (+7.81%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.28 +0.00 (+0.12%) As of 08/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Alpha Teknova NASDAQ:TKNO$4.23 -0.11 (-2.53%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.08 -0.15 (-3.55%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.Tvardi Therapeutics NASDAQ:TVRD$23.92 +0.80 (+3.46%) As of 08/8/2025 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale